Linezolid is a novel and effective treatment for septic pulmonary embolism.
Septic pulmonary embolism (SPE) is an uncommon and severe infectious disease that requires early diagnosis and proper antibiotic therapy. We present the case of a healthy 14-year-old girl with a history of atopic dermatitis, who developed SPE caused by Staphylococcus aureus bacteremia. We initially administered intravenous doripenem and vancomycin. Four days after her admission, blood and urine cultures yielded penicillinase nonproducing, methicillin-sensitive S aureus, with a minimum inhibitory concentration less than 0.06 μg/mL. However,the administration of penicillin G aggravated her condition; therefore, treatment was switched to linezolid on day 8. Her condition subsequently resolved, and she was discharged 40 days after admission without any complications. To our knowledge, this is the first report regarding the efficacy of linezolid for SPE that is related to community-acquired methicillin-sensitive S aureus bacteremia. The favorable lung tissue transfer of linezolid may have contributed to its efficacy against the SPE.